Table 3. Effect of GSTP1 genotype on... | American Society of Hematology

Table 3.

Effect of GSTP1 genotype on progression-free survival and overall survival for patients treated with ABCM and CVAMP/HDM

	Progression-free survival					Overall survival
	Median survival, mo	Adjusted hazard ratio^*	95% CI	Median survival, mo	Adjusted hazard ratio^*	95% CI
ABCM†
Overall	21.0	NA	NA	44.7	NA	NA
Ile/Ile	16.6	1	NA	39.3	1	NA
Ile/Val	21.6	0.55	0.32-0.96	51.8	0.65	0.34-1.25
Val/Val	27.8	0.52	0.28-0.96	48.5	0.78	0.39-1.58
CVAMP/HDM‡
Overall	34.3	NA	NA	58.5	NA	NA
Ile/Ile	43.9	1	NA	65.2	1	NA
Ile/Val	27.3	1.60	0.95-2.69	52.3	1.71	0.93-3.14
Val/Val	29.4	1.60	0.81-3.17	49.1	1.76	0.78-3.98

	Progression-free survival					Overall survival
	Median survival, mo	Adjusted hazard ratio^*	95% CI	Median survival, mo	Adjusted hazard ratio^*	95% CI
ABCM†
Overall	21.0	NA	NA	44.7	NA	NA
Ile/Ile	16.6	1	NA	39.3	1	NA
Ile/Val	21.6	0.55	0.32-0.96	51.8	0.65	0.34-1.25
Val/Val	27.8	0.52	0.28-0.96	48.5	0.78	0.39-1.58
CVAMP/HDM‡
Overall	34.3	NA	NA	58.5	NA	NA
Ile/Ile	43.9	1	NA	65.2	1	NA
Ile/Val	27.3	1.60	0.95-2.69	52.3	1.71	0.93-3.14
Val/Val	29.4	1.60	0.81-3.17	49.1	1.76	0.78-3.98

NA indicates not applicable.

Hazard ratios are adjusted for age, sex, and levels of hemoglobin, creatinine, and B₂M.

P = .04 for adjusted hazard ratio for ABCM PFS and OS.

P = .16 for adjusted hazard ratio for CVAMP/HDM PFS and OS.